Clinical Trials | September 23, 2025
Teva unveils promising SOLARIS resultsfor Olanzapine LAI
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
mRNA-1010 demonstrated superior relative vaccine efficacy
Subscribe To Our Newsletter & Stay Updated
